Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IPHAthis companyInnate Pharma S.A.	$1.45	-2.81×	-6.14×	47.79×	-2.92×	-111.3%	100.0%	-1916.9%	-1764.5%	226.7%	-153.3%	-26.2%	-1.04×	0.13×	-121.42×	1.27×	0.0%	4	-22.77	2	C
NVONovo Nordisk A/S	$40.96	14.03×	7.42×	4.66×	9.85×	95.4%	81.0%	41.3%	33.1%	52.8%	29.5%	2.0%	0.67×	0.67×	30.34×	0.8×	3.6%	6	3.76	4	A-
MDTMedtronic Plc	$102.57	22.22×	2.16×	2.94×	13.54×	65.5%	65.0%	17.8%	13.2%	9.7%	6.1%	5.1%	0.57×	2.65×	9.04×	2.13×	3.4%	9	3.07	4	A-
SNYSanofi	$47.77	12.89×	1.41×	2.15×	9.08×	162.3%	72.1%	20.5%	16.7%	10.9%	7.7%	10.1%	0.28×	1.02×	15.33×	1.09×	5.3%	7	1.58	3	B+
ARGXargenx SE	$940.56	39.78×	7.04×	12.41×	36.72×	-673.4%	89.1%	25.4%	31.1%	17.6%	14.3%	1.6%	0.01×	-2.6×	258.36×	5.23×	0.0%	4	20.05	1	C-
GMABGenmab A/S	$53.61	19.91×	3.28×	5.14×	17.1×	-90.1%	91.7%	33.6%	25.9%	16.5%	8.5%	6.0%	0.93×	2.78×	20.49×	2.02×	0.0%	5	22.67	3	B
Peer median	—	19.91×	3.28×	4.66×	13.54×	65.5%	81.0%	25.4%	25.9%	16.5%	8.5%	5.1%	0.57×	1.02×	20.49×	2.02×	3.4%	6	3.76	3	—